Rigel Pharmaceuticals, Inc.
RIGL
$26.55
$0.602.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.11% | -31.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.49% | -31.69% | |||
| Cost of Revenue | 37.45% | 6.90% | |||
| Gross Profit | -7.31% | -36.53% | |||
| SG&A Expenses | 3.65% | -1.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.62% | 1.13% | |||
| Operating Income | -18.47% | -53.49% | |||
| Income Before Tax | -17.76% | -53.95% | |||
| Income Tax Expenses | -87,525.36% | -175.88% | |||
| Earnings from Continuing Operations | 860.81% | -53.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 860.81% | -53.20% | |||
| EBIT | -18.47% | -53.49% | |||
| EBITDA | -18.10% | -52.97% | |||
| EPS Basic | 851.86% | -53.60% | |||
| Normalized Basic EPS | -18.53% | -54.34% | |||
| EPS Diluted | 827.79% | -55.49% | |||
| Normalized Diluted EPS | -20.42% | -56.34% | |||
| Average Basic Shares Outstanding | 0.94% | 0.86% | |||
| Average Diluted Shares Outstanding | 3.33% | 5.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||